Asuragen and Illumina will join forces to develop and commercialise genomics-based companion diagnostics. The collaboration between the two companies is part of a larger effort by Illumina, which has been working with partners in Europe for several years on its own genome sequencing technology.
Asuragen and Illumina will join forces to develop and commercialise genomics-based companion diagnostics. The partnership will utilise Asurgen's Quantidex NGS product platform in conjunction with Illumina's MiSeqDx instrument.